Abstract:Tau is involved in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease and Frontotemporal dementia. Reduction of soluble tau in those diseases has been described previously with unknown pathological roles. Previously, tau-/- mice were found to lack abnormalities of the central nervous system or behavioral deficits up to 7 months of age. We hypothesized that aged tau-/- mice may develop a neurodegenerative phenotype with more advanced age. Tau-/- mice and background C57BL6/SV129 control mice, at 6, 12, and 24months of age, were weighed and analyzed by performance studies including pole test, rotarod test, open field test and Y maze, before being sacrificed for biochemical studies. For MRI, sacrificed animals were positioned in a stereotactic animal cradle with an anatomically shaped surface coil positioned on top of the head, and scanned with a Bruker Biospec 47/30 scanner. Tyrosine hydroxylase staining was used for stereological estimation of nigral neurons. Dopamine was measured by electrochemical HPLC. The body weight of tau-/- mice did not change with aging, however a significant reduction was found in brain wet weight of aged tau-/- mice (12m and 24m) compared to age-matched background controls. This accompanied neural cortical atrophy evidenced by both T1-MRI scan, decreased brain slice surface area (including decreased cortex and striatum), and increased lateral ventricular size. The corpus callosum was not affected. Behaviorally, the aged tau-/- mice exhibited cognitive impairment evidenced by reduced time spent in the novel arm of Y maze. The tau-/- mice also expressed gradual loss of motor function between 6 and 12 months of age, evidenced by less time maintained in the rotarod test, more time to turn in the pole test and reduced locomotion distance and velocity in the open field test. This motor impairment was ameliorated by oral treatment of Levodopa, a drug for Parkinson's disease. Further analysis indicated substania nigra (SN) neuronal loss in aged tau-/- mice accompanied with striatal dopamine reduction. Aged tau-/- mice express a previously unknown phenotype of neurodegenerative diseases. Soluble tau is needed to maintain brain neurons with age.

Aging-associated REGγ proteasome decline predisposes to tauopathy

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Upregulation of GSK3β Contributes to Brain Disorders in Elderly REGγ-knockout Mice

Upregulation of GSK3 β Contributes to Brain Disorders in Elderly REG γ -knockout Mice

REGγ Deficiency Promotes Premature Aging Via the Casein Kinase 1 Pathway.

Dysregulation of baseline and learning-dependent protein degradation in the aged hippocampus

O4‐08‐03: Loss of Tau Induces Age‐dependent Neurodegeneration

Pathogenic Tau Accelerates Aging-Associated Activation of Transposable Elements in the Mouse Central Nervous System

Retromer deficiency in Tauopathy models enhances the truncation and toxicity of Tau

Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies

Astrocyte senescence and SASP in neurodegeneration: tau joins the loop

Aging as a Precipitating Factor in Chronic Restraint Stress-Induced Tau Aggregation Pathology, and the Protective Effects of Rosmarinic Acid

Convergence of presenilin- and tau-mediated pathways on axonal trafficking and neuronal function.

Altered Proteasome Composition in Aging Brains, Genetic Proteasome Augmentation Mitigates Age-Related Cognitive Declines, and Acute Proteasome Agonist Treatment Rescues Age-Related Cognitive Deficits in Mice

RPS23RG1 modulates tau phosphorylation and axon outgrowth through regulating p35 proteasomal degradation

Reduced progranulin increases tau and α-synuclein inclusions and alters mouse tauopathy phenotypes via glucocerebrosidase

Tau protein modulates an epigenetic mechanism of cellular senescence in human SH-SY5Y neuroblastoma cells

P2-296: Enhanced Proteolysis of Aβ Peptide Reduces Tau Phosphorylation and Neurofibrillary Tangle Formation in APP/tau Transgenic Mice

The Mechanistic Link Between Tau-Driven Proteotoxic Stress and Cellular Senescence in Alzheimer's Disease

Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss

Broad activation of the PRKN pathway triggers synaptic failure by disrupting synaptic mitochondrial supply in early tauopathy